This press release provides a clear positive data update that strengthens the probability of success for NXC-201. The next catalyst is the September 2026 update, with a more significant milestone in March 2027 (1-year follow-up / BLA submission). Traders should watch for potential near-term price momentum and any subsequent financing or partnership announcements. Given the small-cap biotech profile, volatility is expected.
Price Chart
Executive Summary
Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR), boosting the NEXICART-2 CR rate to 95% (19/20). All CRs were reached within 1 year, with no relapses observed. All subsequently enrolled patients with available MRD results are MRD-negative at one month. These results support initiating a randomized Phase 3 trial in newly diagnosed AL Amyloidosis. Given early-stage biotech status and potentially registrational data, this is a bullish catalyst for IMMX.
Key Facts
- NEXICART-2 CR rate is now 95% (19/20 patients)
- All four MRD-negative patients from ASH 2025 converted to CR
- All CRs reached within 1 year of follow-up post-dosing; no relapses to date
- All subsequently enrolled patients with MRD data are MRD-negative at one month
- Next NEXICART-2 update expected late September 2026
- Company expects 1-year follow-up data by end of March 2027 to drive BLA submission and commercial launch
- NXC-201 has Breakthrough Therapy Designation, RMAT, and Orphan Drug Designation from FDA/EMA
- Estimated U.S. relapsed/refractory AL Amyloidosis patient population ~38,500 in 2026, market expected to reach $6B in 2025
Financial Impact
Potential multi-blockbuster market in a $6B+ indication; early-stage biotech with no current revenue, but a 95% CR rate in a heavily pretreated population represents strong efficacy that could support accelerated approval and eventual commercial launch.
Risk Factors
- Phase 3 trial results may not confirm Phase 2 efficacy
- Regulatory approval not guaranteed despite BTD/RMAT designations
- Cash runway may require additional financing before commercial launch
- Competitive landscape includes other BCMA-targeted CAR-T therapies
- Risk of manufacturing or safety issues as trial expands
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299108 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $10.23 $9.29 | ▲ +9.19% | ▲ +10.49% | $8.06 (+21.21%) |
Sep 29, 2026 27d ago | 424B5 | $10.54 $9.64 | ▲ +8.54% | ▲ +10.49% | $8.06 (+23.53%) |
Sep 29, 2026 27d ago | 8-K | $10.54 $9.64 | ▼ −8.54% | ▼ −10.49% | $8.06 (−23.53%) |
Jul 20, 2026 14w ago | 8-K | $8.80 $8.52 | ▼ −3.18% | ▼ −2.76% | $8.06 (−8.41%) |
May 21, 2026 22w ago | 8-K | $8.78 $9.22 | ▼ −5.01% | ▼ −3.35% | $8.06 (+8.20%) |
May 21, 2026 22w ago | Press Release | $8.67 $9.00 | ▲ +3.81% | ▲ +1.96% | $8.06 (−7.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers